31 May 2018: Pharmaceutical Research
Dendrobium Officinale Kimura et Migo Ameliorates Insulin Resistance in Rats with Diabetic Nephropathy
Ming Zhao BCD 1, Jungang Han AEF 1*
DOI: 10.12659/MSMBR.909242
Med Sci Monit Basic Res 2018; 24:84-92
Abstract
BACKGROUND: Emerging evidence suggests the potential of Dendrobium officinale Kimura et Migo (DO) in treating the complications of diabetes mellitus (DM). We evaluated the therapeutic potential of DO in treating diabetic nephropathy (DN) by preventing insulin resistance.
MATERIAL AND METHODS: A DN model was established. Mean glomerular volume of rats was estimated by the method of Weibel-Gomez. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to determine the expression of mRNAs and we used Western blot assay to determine the expression of proteins. The levels of fasting insulin (FINS) and glucagon (GLU) were measured and we assessed the levels of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-a (TNF-a), and interleukin-6 (IL-6) using the enzyme-linked immunosorbent assay (ELISA).
RESULTS: Compared with the Normal rats, the levels of urinary glucose, albuminuria, Scr, albuminuria/Scr and BUN, and the expression levels of CaN, TLR-2, TLR-4, MyD88, hs-CRP, TNF-a, and IL-6, the level of FINS, GLU, and HOMAIR were increased in DN, DO 1.0, DO 2.0, and DMBG groups. Compared with the DN rats, in DO 1.0, DO 2.0, and DMBG groups the glomerular volume was smaller, the levels of urinary glucose, albuminuria, Scr, albuminuria/Scr, and BUN, the expression levels of CaN, TLR-2, TLR-4, MyD88, hs-CRP, TNF-a, and IL-6, the level of FINS, GLU, and HOMA-IR were decreased.
CONCLUSIONS: We found that DO prevents insulin resistance in rats with DN. This may be associated with reduction of TLRs and inflammatory response, which should be further verified by loss of DO effects on DN after treatment of inhibitors of TLRs.
Keywords: Cytokines, Insulin Resistance, Toll-Like Receptors
Background
Diabetes mellitus (DM) is a heterogeneous metabolic disorder resulting from variable degrees of insulin resistance and a progressive reduction in insulin secretion, and it is associated with a higher risk of microvascular/macrovascular disease [1,2]. DM is known to cause nephropathic retinopathy and neuropathy. Diabetic nephropathy (DN) is an important long-term microvascular complication of uncontrolled hyperglycemia, which develops in approximately 30% to 40% of all DM patients [3]. The initiation of microalbuminuria is widely considered as the first clinical sign of DN, which results in macroalbuminuria and subsequent reduction in glomerular filtration rate (GFR) [4]. DN is a major cause of end-stage renal disease (ESRD) and its pathophysiology appears to be involved in the interaction between insulin resistance and inflammation [5]. It is likely that a novel therapeutic strategy targeting this interaction would effectively prevent and slow the progression of DN.
Traditional Chinese medicine (TCM) has been widely used for clinical treatment in China for centuries and recently is becoming popular across the globe, especially in the treatment and management of DM and its complications. However, more extensive investigation of their effectiveness and safety and their underlying mechanisms are still urgently needed [6,7]. Dried stems of the plant
Material and Methods
EXPERIMENTAL ANIMALS:
Fifty 8-week-old female Sprague-Dawley (SD) rats (SPF grade), purchased from Shanghai Silaike Laboratory Animal Company (license No. SCXK2007-0005), were raised in our laboratory and given free access to drinking water and food. After 1-week adaptation, in 50 selected Sprague-Dawley rats, we randomly allocated 10 rats into a normal group and 40 rats were used for establishment of DN models. The normal group received an intraperitoneal injection of sodium citrate buffer (pH 4.5) and the model group was fed a high-fat/sucrose diet (41.4 kJ/kg) including 10% lard, 20% sucrose, 2.5% cholesterol, 1.0% cholate, and 66.5% basal feed. Four weeks later, these rats underwent an overnight 12–16 h fast and received a single intraperitoneal injection of 0.5% streptozotocin (STZ, 30 mg/kg, every 2 weeks, twice, Sigma-Aldrich Biotech., St. Louis, MO). One week after the last injection, blood samples were collected from the tail vein of STZ-treated rats. Fasting blood glucose ≥7 mmol/L lasting for 2 weeks indicated successful establishment of T2DM models. Subsequently, these T2DM rats were fed a high-fat/sucrose diet for 8 weeks. T2DM rats had random glycemia ≥16 mmol/L with low insulin sensitivity, and trace albuminuria, indicating successful establishment of the diabetic nephropathy model [12]. The study protocols were approved by the Animal Ethics Committee and were in strict accordance with the International Association for the Study of Pain (IASP) ethics guidelines for the use of awake animals in pain research.
EXTRACTION OF DO AND ANIMAL TREATMENT:
DO (purchased from Bright Food Group, Yunnan Dendrobium Biotechnology Development Co., Ltd.) was dried and shattered. After passing through a 10-mesh screen, 250 g of DO powder was immersed in 2.5 L water, and 1 h later was boiled for 30 min. The juice obtained was concentrated 3 times to 125 ml (equal to 2 g/ml of crude DO extractum). Successfully established 40 DN models were randomly assigned to DN, DO 1.0, DO 2.0, and DMBG groups. The rats in DO 1.0 were given intragastric administration of 5 ml/kg/day DO, those in the DO 2.0 group were given intragastric administration of 10 ml/kg/day DO, and those in the DMBG group were treated by 0.0042 g/kg/day dimethylbiguanide (DMBG). The DMBG was purchased from Sigma-Aldrich Biotech. (St. Louis, MO). Those rats in the normal and DN rats were given same volume of menstruum. After treatment, no rats received insulin and they were given free access to drinking water and food. Observation lasted for 4 weeks.
SPECIMEN COLLECTION:
Twenty-four-hour urine samples were collected from rats in each group, centrifuged at 3000 rpm for 15 min, and stored at −80°C. Rat tail arterial pressure was measured using the RBP-1 rat tail blood pressure measuring instrument (QianSheng Biotech. Shanghai). The rats were subjected to intraperitoneal injection of 3% pentobarbital sodium (0.1 ml/100g) for anesthesia, followed by right common carotid artery ligation. Collected blood samples were centrifuged at 3000 rpm for 15 min to separate plasma. The plasma was stored at −80°C until further use. The left kidney was removed from each rat, weighed, frozen in liquid nitrogen, and stored at −80°C until further use. After the kidney surfaces were completely blanched by continuous irrigation using near-freezing saline (4°C), the right kidney was cut into slices 8 mm in length, fixed in 4% paraformaldehyde, and embedded in paraffin. Additionally, the renal cortex (l×l×l mm) was collected and fixed in 2.5% glutaraldehyde.
LABORATORY DATA:
The levels of blood glucose, total cholesterol (TC), triglyceride (TG), serum creatinine (Scr), alanine aminotransferase (AST), and aspartate aminotransferase (ALT) were measured in our laboratory. The concentration of albuminuria (g/L) was determined using Coomassie Brilliant Blue (CBB) staining method according to the kit’s instruction. The concentration of urinary glucose (mmol/L) was tested by the glucose-oxidase/peroxidase method. The concentration of blood urea nitrogen (mmol/L) (BUN) was measured by FEARON’S color reaction according to the kit’s instruction.
PERIODIC ACID SCHIFF (PAS) STAINING:
The slices were dewaxed in xylene, rehydrated in graded alcohol, and oxidized in 1% periodic acid for 15 min. After rinsing with distilled water, the slices were immersed in Schiff reagent for 30 min, stained with hematoxylin for 1.5 min, and rinsed with 1% hydrochloric acid ethanol. Subsequently, the slices were blued in ammonia, lasting for 5 s. Thereafter, all samples were examined using light microscopy. Mean values for glomerular cross-sectional area were estimated by computer-assisted image analysis. Glomerular volume=β/k×(area)3/2 with β=1.38 and k=1.1.
REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR):
Total RNA was isolated from the tissues using TRIzol kits (Invitrogen, Carlsbad, CA) according to the manufacturers’ instructions. The RNA was dissolved in diethylpyrocarbonate (DEPC)-treated ultrapure water. The quality of the RNA was determined by the ratio of optical density (OD) at 260 nm to that at 280 nm using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). The TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) was used for the preparation of cDNA (Applied Biosystems, Foster City, CA). The PCR reaction system was prepared according to kit’s instructions (59–20063, Fermentas GmbH, St. Leon Rot, Germany). The primer sequences used are listed in Table 1. The PCR reaction conditions were: pre-denaturation at 95°C for 30 s, followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 20 s, and extension at 70°C for 10 s. PCR was performed using a Bio Rad iQ5 Real Time PCR instrument (Bio Rad Laboratories, Hercules, CA). β-actin was used as a loading control. The data were analyzed using 2−ΔΔCt method. ΔCt=Ct (target gene)–Ct (loading control), ΔΔCt=ΔCt (experimental group)–ΔCt (control group). The experiment was conducted 3 times to obtain the average value.
WESTERN BLOT:
The protein extracted from the tissues was boiled for 5 min in sample buffer, separated in 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto a nitrocellulose filter (NC) membrane, blocked for 1 h with Tris-buffered saline plus 0.1% Tween 20 (TBST) containing 5% bovine serum albumin (BSA) at room temperature, and probed overnight at 4°C with the following rabbit anti-mouse antibodies: TLR2 (1: 200); TLR4 (1: 200); MyD88 (1: 500); CaN (1: 1000); β-actin (1: 1500). All primary antibodies were purchased from Santa Cruz Biotechnology, Inc, Santa Cruz, CA. After rinsing 3 times with TBST (for 15 min each time), we added diluted goat anti-rabbit immunoglobulin G (IgG) (Abcam Inc., Cambridge, MA, USA) to the membrane at 4°C. At 4–6 h later, the membrane was rinsed 3 times with TBST thrice (for 15 min each time). Chemiluminescence reagent A solution and B solution were mixed at a ratio of 1: 1 and the mixture was added dropwise on the membrane for visualization.
ESTIMATION OF INSULIN RESISTANCE:
The levels of fasting insulin (FINS), glucagon (GLU), and homeostasis model of assessment insulin resistance (HOMA-IR) together indicated insulin resistance. The renal tissues (150–200 mg) in each group were obtained for preparation of homogenate. The levels of FINS and GLU were determined using a radioimmunoassay according to the manufacturer’s instructions (Beijing North Biotechnology Research Institute, China). The homogenate was incubated in the kit at 37°C for 2 h and mixed with 500 μl of separating agent, and the mixture was centrifuged at 3500 rpm for 15 min. HOMA-IR=FINS (μIU/mL)×Fasting blood glucagon (mmol/L)/22.5.
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA):
The renal tissues were homogenized, coated, and incubated overnight at 4°C in an ELISA plate (Shanghai Alpha Biotechnology Co. Ltd., China). The plate was rinsed 3 times with phosphate-buffered saline (PBS) containing Tween20 0.05% (PBST) and blocked for 1 h with 1% BSA at 37°C. After rinsing 3 times with PBST again, to each well in the plate, we added Chemiluminescence reagent A solution and B solution (Shanghai Alpha Biotechnology Co. Ltd., China). Ten minutes later, 2 mo1/L of H2SO4 was added to terminate the reaction. Optical density (OD) at 540 mm was assessed. The levels of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were determined by use of the appropriate kits (Wuhan Boster Biological Technology Ltd., Wuhan, Hubei, China) according to manufacturer’s instructions.
STATISTICAL ANALYSIS:
The statistical software package SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Measurement data are expressed as mean ± standard deviation. The
Results
DO REDUCED FASTING BLOOD GLUCOSE, FASTING INSULIN, AND BLOOD PRESSURE:
The rats in the normal group had normal eating and drinking behaviors, as well as normal mental state and daily activity. No rats died. Three days after injection of STZ, the rats developed polydipsia, polyuria, and polyphagia, and these signs became worse as the disease duration increased. At the 4th week, STZ-injected rats had pale hair and showed a slow response. Compared with the rats in the normal group, the rats in DN, DO 1.0, DO 2.0, and DMBG groups had lower body weights (P<0.05), while compared with the rats in the DN group, rats in the DO 1.0, DO 2.0, and DMBG groups were heavier (P>0.05). Compared with the normal group, DN, DO 1.0, DO 2.0, and DMBG group rats had increased kidney weights relative to body weight. Compared with the DN group, levels of fasting blood glucose, fasting insulin, and blood pressure in the DO 2.0 and DMBG groups were decreased (P<0.05), with no significant difference recorded among normal, DO 2.0, and DMBG groups. Blood pressures in the DO 2.0 and DMBG groups were significantly lower than in the DN group. These data suggest that DO reduced fasting blood glucose, fasting insulin, and blood pressure in the rats with DN. The level of blood glucose was lower in the DO 2.0 than in the DO 1.0 group, although the difference was not significant (P>0.05) and there was no significant difference between DO 2.0 and DMBG groups (P>0.05, Table 2).
DO IMPROVED RENAL FUNCTION IN RATS WITH DN:
As shown in Table 3, compared with the normal group, DN, DO 1.0, DO 2.0, and DMBG groups had increased levels of urinary glucose, albuminuria, Scr, and BUN (P<0.05). Compared with the DMBG group, DO 1.0 and DO 2.0 groups had increased levels of urinary glucose, albuminuria, Scr, and BUN (P<0.05). The levels of urinary glucose, albuminuria, Scr, albuminuria/Scr, and BUN were lower in the DO 2.0 group than in the DO 1.0 group, although the difference was not significant (P>0.05). These indicators did not differ between DO 2.0 and DMBG groups (P>0.05).
DO EXERTED NO SIGNIFICANT EFFECT ON BLOOD LIPIDS OR LIVER FUNCTION IN THE RATS WITH DN:
As shown in Table 4, DN, DO 1.0, DO 2.0, and DMBG groups showed higher levels of TC and TG compared with the normal group (P<0.05); however, the levels of TC and TG did not change among DN, DO 1.0, DO 2.0, and DMBG groups (P>0.05). The levels of AST and ALT did not differ among the 5 groups (P>0.05), suggesting that DO exerted no significant effect on blood lipids or liver function in the rats with DN.
DO REDUCED THE ACTIVITY OF CAN IN RATS WITH DN:
We found that the expression level of CaN protein did not differ with the activity of CaN, and the expression level of CaN protein reflected the activity of CaN. Compared with the normal group, the expression levels of CaN protein were elevated in the DN, DO 1.0, DO 2.0, and DMBG groups (P<0.05). Compared with the DN group, DO 1.0, DO 2.0, and DMBG groups exhibited higher expression levels of CaN protein (P<0.05), suggesting that DO reduced the activity of CaN in rats with DN. The expression level of CaN protein was decreased in the DO 2.0 group compared with the DO 1.0 group, but the difference was no significant (P>0.05). No significant difference was found in CaN activity between the DO 2.0 and DMBG groups (P>0.05, Figure 1).
DO DECREASED THE EXPRESSION OF TLRS IN RATS WITH DN:
Compared with the normal group, the expression levels of TLR2, TLR4 and MyD88 mRNA and protein were higher in the DN, DO 1.0, DO 2.0, and DMBG groups (P<0.05). In comparison with the DN group, DO 1.0, DO 2.0, and DMBG groups had lower expression levels of TLR2, TLR4, MyD88 mRNA, and protein (P<0.05), suggesting that DO decreased the expression of TLRs in rats with DN. The DO 2.0 group had lower expression levels of TLR2, TLR4, and MyD88 mRNA and protein compared with the DO 1.0, but the difference was not significant (P>0.05). No significant difference was found in the expression levels of TLR2, TLR4, and MyD88 mRNA and protein between DO 2.0 and DMBG groups (P>0.05, Figure 2).
DO REDUCED INSULIN RESISTANCE IN THE RATS WITH DN:
As shown in Figure 3, in comparison with the normal group, the level of FINS, GLU, and HOMA-IR were higher in the DN, DO 1.0, DO 2.0, and DMBG groups (P<0.05). Compared with the DN group, the levels of FINS, GLU, and HOMA-IR were lower in the DO 1.0, DO 2.0, and DMBG groups (P<0.05). The levels of FINS, GLU, and HOMA-IR were lower in the DO 2.0 group than in the DO 1.0 group. No significant difference was found between DO 2.0 and DMBG groups (P>0.05). These findings indicate that DO reduced insulin resistance in rats with DN.
DO ATTENUATED INFLAMMATORY RESPONSE IN THE RATS WITH DN:
Compared with the normal group, the levels of hs-CRP, TNF-α, and IL-6 were higher in the DN, DO 1.0, DO 2.0, and DMBG groups (P<0.05). In comparison with the DN group, the levels of hs-CRP, TNF-α, and IL-6 were lower in the DO 1.0, DO 2.0, and DMBG groups (P<0.05), suggesting that DO attenuated inflammatory response in the rats with DN. Compared with the DO 1.0 group, the DO 2.0 group had decreased levels of hs-CRP, TNF-α, and IL-6. No significant difference was found in the levels of hs-CRP, TNF-α, and IL-6 between the DO 2.0 and DMBG groups (P>0.05, Table 5).
Discussion
TCM has been widely used in the treatment of complex chronic diseases due to fewer side-effects, relatively lower cost, and better patient tolerance [13]. Modern pharmacological research has shown the biological properties of TCMs in treating DM, including antioxidant [14], antihyperglycemia [15], anti-lipid peroxidation, and anti-inflammatory effects [16]. He et al. evaluated antidiabetic potential of selected TCMs in mice with DM and found that 13 out of the selected 34 herbs exhibited a significant effect in decreasing hyperglycemia [17]. However, previous studies that investigated the therapeutic role for treating complications of DM were very limited. The present study evaluated the therapeutic potential of 5 and 10 ml/kg/d DO in treating DN by preventing insulin resistance.
One of the most important findings of the present study is that
Another important finding in our study is that
Conclusions
In conclusion, we demonstrated the therapeutic potential of 5 and 10 ml/kg/d DO in treating diabetic nephropathy (DN) by preventing insulin resistance. The present study provides a better understanding of relative significance of
References
1. Zaccardi F, Webb DR, Yates T, Davies MJ, Pathophysiology of type 1 and type 2 diabetes mellitus: A 90-year perspective: Postgrad Med J, 2016; 92; 63-69, pmid: 26621825
2. Horton WB, Boler PL, Subauste AR, Diabetes mellitus and the skin: Recognition and management of cutaneous manifestations: South Med J, 2016; 109; 636-46, pmid: 27706502
3. Pezzolesi MG, Poznik GD, Skupien J, An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes: Kidney Int, 2011; 80; 105-11, pmid: 21412220
4. Yokoyama H, Sone H, Oishi M, Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: The Japan Diabetes Clinical Data Management study (JDDM15): Nephrol Dial Transplant, 2009; 24; 1212-19, pmid: 18984626
5. Saraheimo M, Forsblom C, Hansen TK, Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy: Diabetologia, 2005; 48; 198-202, pmid: 15616805
6. Zhang H, Zhao T, Gong Y, Attenuation of diabetic nephropathy by Chaihuang-Yishen granule through anti-inflammatory mechanism in streptozotocin-induced rat model of diabetics: J Ethnopharmacol, 2014; 151; 556-64, pmid: 24269779
7. Lian F, Wu L, Tian J, The effectiveness and safety of a danshen-containing Chinese herbal medicine for diabetic retinopathy: A randomized, double-blind, placebo-controlled multicenter clinical trial: J Ethnopharmacol, 2015; 164; 71-77, pmid: 25666427
8. Tang H, Zhao T, Sheng Y: Evid Based Complement Alternat Med, 2017; 2017; 7436259, pmid: 28386292
9. Zhang Z, Zhang D, Dou M: Biomed Pharmacother, 2016; 84; 1350-58, pmid: 27802903
10. Mudaliar H, Pollock C, Panchapakesan U, Role of Toll-like receptors in diabetic nephropathy: Clin Sci (Lond), 2014; 126; 685-94, pmid: 24490813
11. Zheng XY, Wei RB, Shi SZ, Effects of Fufang Shenhua Tablet on the expression of toll-like receptors during acute kidney injury induced by ischemia-reperfusion in rats: Chin J Integr Med, 2012; 18; 918-24, pmid: 23239000
12. Lin S, Yang J, Wu G, Preventive effect of taurine on experimental type II diabetic nephropathy: J Biomed Sci, 2010; 17(Suppl 1); S46, pmid: 20804623
13. Cai Q, Lin J, Wei L: Int J Mol Sci, 2012; 13; 6117-28, pmid: 22754353
14. Liu W, Ogata T, Sato S, Superoxide scavenging activities of sixty Chinese medicines determined by an ESR spin-trapping method using electrogenerated superoxide: Yakugaku Zasshi, 2001; 121; 265-70, pmid: 11305043
15. Shu XS, Lv JH, Tao J: J Ethnopharmacol, 2009; 124; 539-43, pmid: 19454312
16. Schinella GR, Tournier HA, Prieto JM, Antioxidant activity of anti-inflammatory plant extracts: Life Sci, 2002; 70; 1023-33, pmid: 11860151
17. He K, Li X, Chen X, Evaluation of antidiabetic potential of selected traditional Chinese medicines in STZ-induced diabetic mice: J Ethnopharmacol, 2011; 137; 1135-42, pmid: 21798327
18. HC Advances in research on mechanism of TCM for invigorating blood and enriching Qi working against renal ischemic-reperfusion injury: Global Traditional Chinese Medicine, 2012; 5; 63-66 [in Chinese]
19. Liao M, Chen X, Han J, Selective expression of Huntingtin-associated protein 1 in {beta}-cells of the rat pancreatic islets: J Histochem Cytochem, 2010; 58; 255-63, pmid: 19901268
20. Lin X, Gao CHMechanism of dendrobium compound to promote proliferation of islet cell by GLP-1/β-Catenin signaling pathway: China Journal of Traditional Chinese Medicine & Pharmacy, 2016; 31; 3266-69 [in Chinese]
21. Li TM, Deng MZEffect of dendrobium mixture on hypoglycemic and the apoptosis of islet in rats with type 2 diabetic mellitus: Zhong Yao Cai, 2012; 35; 765-69, pmid: 23213742 [in Chinese]
22. Pan LH, Li XF, Wang MN: Int J Biol Macromol, 2014; 64; 420-27, pmid: 24370475
23. Veloso CA, Fernandes JS, Volpe CM, TLR4 and RAGE: Similar routes leading to inflammation in type 2 diabetic patients: Diabetes Metab, 2011; 37; 336-42, pmid: 21377387
24. Nackiewicz D, Dan M, He W, TLR2/6 and TLR4-activated macrophages contribute to islet inflammation and impair beta cell insulin gene expression via IL-1 and IL-6: Diabetologia, 2014; 57; 1645-54, pmid: 24816367
25. Teixeira da Silva JA, Tsavkelova EA, Zeng S: Planta, 2015; 242; 1-22, pmid: 25940846
26. MacLeod H, Wetzler LM, T cell activation by TLRs: A role for TLRs in the adaptive immune response: Sci STKE, 2007; 2007; pe48, pmid: 17785715
27. Arumugam TV, Okun E, Tang SC, Toll-like receptors in ischemia-reperfusion injury: Shock, 2009; 32; 4-16, pmid: 19008778
28. Aslam R, Speck ER, Kim M: Blood, 2006; 107; 637-41, pmid: 16179373
29. Souza PP, Palmqvist P, Lundgren I, Stimulation of IL-6 cytokines in fibroblasts by toll-like receptors 2: J Dent Res, 2010; 89; 802-7, pmid: 20505053
30. Fousteris E, Melidonis A, Panoutsopoulos G, Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction: Cardiovasc Diabetol, 2011; 10; 101, pmid: 22104207
Most Viewed Current Articles
13 Apr 2020 : Original article 19,586
Outcome of 24 Weeks of Combined Schroth and Pilates Exercises on Cobb Angle, Angle of Trunk Rotation, Chest...DOI :10.12659/MSMBR.920449
Med Sci Monit Basic Res 2020; 26:e920449
20 Apr 2018 : Original article 17,466
Brain Training Games Enhance Cognitive Function in Healthy SubjectsDOI :10.12659/MSMBR.909022
Med Sci Monit Basic Res 2018; 24:63-69
23 Jul 2016 : Review article 10,353
Cardiac Hypertrophy: An Introduction to Molecular and Cellular BasisDOI :10.12659/MSMBR.900437
Med Sci Monit Basic Res 2016; 22:75-79
10 Aug 2020 : Clinical Research 9,788
Effects of Cognitive Task Training on Dynamic Balance and Gait of Patients with Stroke: A Preliminary Rando...DOI :10.12659/MSMBR.925264
Med Sci Monit Basic Res 2020; 26:e925264






